Corresponding Author: Franco Locatelli, MD, PhD, Sapienza, University of Rome, Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Piazza Sant'Onofrio, 4, 00165 Rome, Italy (franco.locatelli@opbg.net).
Accepted for Publication: January 22, 2021.
Author Contributions: Dr Locatelli had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Locatelli, Zugmaier, Morris, Parasole, Micalizzi, Mergen, Peters, Saha, von Stackelberg.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Locatelli, Zugmaier, Morris, Parasole, Mergen, Peters, Saha, von Stackelberg.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Zugmaier, Mohammad.
Administrative, technical, or material support: Morris, Gruhn, Klingebiel, Petit, Eckert, Möricke, Sartor, Saha, von Stackelberg.
Supervision: Locatelli, Zugmaier, Morris, Parasole, Mergen, Eckert, Saha, von Stackelberg.
Contribution to statistical sections of manuscript and revisions/suggestions: Mohammad.
Recruitment of cases, collecting data and information, discussing management of patients, evaluating results: Rizzari.
Conflict of Interest Disclosures: Dr Locatelli reports receiving personal fees from Amgen Speakers' Bureau and advisory board membership, Novartis Speakers' Bureau and advisory board membership, Bellicum Pharmaceuticals advisory board membership, Miltenyi Speakers' Bureau, Jazz Pharmaceutical Speakers' Bureau, Takeda Speakers' Bureau, Neovii advisory board membership, and Medac Speakers' Bureau outside the submitted work. Dr Zugmaier reports receiving personal fees from Amgen outside the submitted work, receiving issue of patents (20190300609, 20130323247, and 20110262440), and having patents pending (10696744, 10662243, 20190142846, 20190142846, 20170327581, 10130638, 9688760, 20170122947, 9486475, 20160208001, 9192665, 20150071928, 8840888, 20140228316, 20140227272, 20130287778, and 20130287774). Dr Rizzari reports receiving personal fees from SOBI Advisory Board during the conduct of the study. Dr Morris reports receiving personal fees from Amgen employee during the conduct of the study and personal fees from and employment at Amgen. Dr Klingebiel reports receiving grants from Amgen GmbH during the conduct of the study. Dr Mergen reports employment by Amgen Research (Munich) GmbH. Ms Mohammad reports being an employee and shareholder of Amgen Ltd. Dr Eckert reports receiving other from Amgen Service for central minimal residual disease quantification during the conduct of the study. Dr Möricke reports receiving other from Amgen Payments to the institution for laboratory work during the conduct of the study. Dr Sartor reports receiving grants from Amgen during the conduct of the study. Dr Hrusak reports receiving grants from Amgen covering costs of minimal residual disease monitoring by cytometry during the conduct of the study. Dr Peters reports receiving personal fees from Amgen during the conduct of the study; grants from Amgen, Medac, Neovii, and Riemser outside the submitted work; and personal fees from Novartis, Amgen, and Jazz outside the submitted work. Dr Saha reports receiving personal fees from Amgen during the conduct of the study. Dr von Stackelberg reports receiving personal fees from Amgen Advisory Board during the conduct of the study and personal fees from Novartis Advisory Board, MorphoSys Advisory Board, Jazz Pharmaceuticals Advisory Board, and Shire Advisory Board outside the submitted work. No other disclosures were reported.
Funding/Support: This study was funded by Amgen Inc.
Role of the Funder/Sponsor: Amgen Inc participated in the conception, design, and conduct of the trial and the analysis and interpretation of data; managed patient data collected at the study sites; and supported the external authors in submitting the results of this clinical trial for publication in JAMA in parallel with the publication of Study AALL1331 from the Children’s Oncology Group. Amgen did not control the decision. Amgen did not have the right to veto publication or to control the decision regarding to which journal the manuscript was submitted.
Group Information: A complete list of principal investigators is provided in the eAppendix in Supplement 3.
Data Sharing Statement: See Supplement 4.
Additional Contributions: Medical writing support was provided by Kathryn Boorer, PhD, of KB Scientific Communications, LLC, funded by Amgen Inc; and Liz Leight, PhD, an employee of Amgen Inc.
3.Krentz
S , Hof
J , Mendioroz
A ,
et al. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2013;27(2):295-304. doi:
10.1038/leu.2012.155
PubMedGoogle ScholarCrossref 4.Malempati
S , Gaynon
PS , Sather
H , La
MK , Stork
LC ; Children’s Oncology Group. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children’s Oncology Group study CCG-1952.
J Clin Oncol. 2007;25(36):5800-5807. doi:
10.1200/JCO.2007.10.7508
PubMedGoogle ScholarCrossref 6.Peters
C , Schrappe
M , von Stackelberg
A ,
et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors: the ALL-SCT-BFM-2003 trial.
J Clin Oncol. 2015;33(11):1265-1274. doi:
10.1200/JCO.2014.58.9747
PubMedGoogle ScholarCrossref 8.von Stackelberg
A , Locatelli
F , Zugmaier
G ,
et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
J Clin Oncol. 2016;34(36):4381-4389. doi:
10.1200/JCO.2016.67.3301
PubMedGoogle ScholarCrossref 10.Locatelli
F , Zugmaier
G , Mergen
N ,
et al. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study.
Blood Cancer J. 2020;10(7):77. doi:
10.1038/s41408-020-00342-x
PubMedGoogle ScholarCrossref 11.Eckert
C , Henze
G , Seeger
K ,
et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
J Clin Oncol. 2013;31(21):2736-2742. doi:
10.1200/JCO.2012.48.5680
PubMedGoogle ScholarCrossref 13.Paganin
M , Zecca
M , Fabbri
G ,
et al. Minimal residual disease is an important predictive factor of outcome in children with relapsed “high-risk” acute lymphoblastic leukemia.
Leukemia. 2008;22(12):2193-2200. doi:
10.1038/leu.2008.227
PubMedGoogle ScholarCrossref 14.Domenech
C , Mercier
M , Plouvier
E ,
et al. First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: results of the Cooprall-97 study.
Eur J Cancer. 2008;44(16):2461-2469. doi:
10.1016/j.ejca.2008.08.007
PubMedGoogle ScholarCrossref 17.van der Velden
VH , Cazzaniga
G , Schrauder
A ,
et al; European Study Group on MRD Detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
Leukemia. 2007;21(4):604-611. doi:
10.1038/sj.leu.2404586
PubMedGoogle ScholarCrossref 20.Brüggemann
M , Schrauder
A , Raff
T ,
et al; European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); International Berlin-Frankfurt-Münster Study Group (I-BFM-SG). Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.
Leukemia. 2010;24(3):521-535. doi:
10.1038/leu.2009.268
PubMedGoogle ScholarCrossref 21.Tallen
G , Ratei
R , Mann
G ,
et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
J Clin Oncol. 2010;28(14):2339-2347. doi:
10.1200/JCO.2009.25.1983
PubMedGoogle ScholarCrossref 22.Handgretinger
R , Zugmaier
G , Henze
G , Kreyenberg
H , Lang
P , von Stackelberg
A . Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia.
Leukemia. 2011;25(1):181-184. doi:
10.1038/leu.2010.239
PubMedGoogle ScholarCrossref 23.Topp
MS , Kufer
P , Gökbuget
N ,
et al. Targeted therapy with the T-cell–engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
J Clin Oncol. 2011;29(18):2493-2498. doi:
10.1200/JCO.2010.32.7270
PubMedGoogle ScholarCrossref 30.Bader
P , Kreyenberg
H , Henze
GH ,
et al; ALL-REZ BFM Study Group. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
J Clin Oncol. 2009;27(3):377-384. doi:
10.1200/JCO.2008.17.6065
PubMedGoogle ScholarCrossref 31.Ruggeri
A , Michel
G , Dalle
JH ,
et al. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.
Leukemia. 2012;26(12):2455-2461. doi:
10.1038/leu.2012.123
PubMedGoogle ScholarCrossref 34.Forero-Castro
M , Montaño
A , Robledo
C ,
et al. Integrated genomic analysis of chromosomal alterations and mutations in B-cell acute lymphoblastic leukemia reveals distinct genetic profiles at relapse.
Diagnostics. 2020;10(7):455. doi:
10.3390/diagnostics10070455Google ScholarCrossref 35.Schmiegelow
K , Attarbaschi
A , Barzilai
S ,
et al; Ponte di Legno Toxicity Working Group. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Lancet Oncol. 2016;17(6):e231-e239. doi:
10.1016/S1470-2045(16)30035-3
PubMedGoogle ScholarCrossref 36.Stein
AS , Schiller
G , Benjamin
R ,
et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors.
Ann Hematol. 2019;98(1):159-167. doi:
10.1007/s00277-018-3497-0
PubMedGoogle ScholarCrossref 38.Martinelli
G , Boissel
N , Chevallier
P ,
et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study.
J Clin Oncol. 2017;35(16):1795-1802. doi:
10.1200/JCO.2016.69.3531
PubMedGoogle ScholarCrossref 39.Brown
PA , Ji
L , Xu
X ,
et al A randomized phase 3 trial of blinatumomab vs chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from Children's Oncology Group Study AALL1331.
Blood. 2019;134(suppl 2):LBA-1. doi:
10.1182/blood-2019-132435Google ScholarCrossref